To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05296798
Title A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | TUR | POL | LBN | ITA | HUN | GBR | FRA | ESP | DEU | BRA | BEL | ARG


No variant requirements are available.